Medications to Manage Gallbladder Disease on Mounjaro (Tirzepatide): First-Line and Beyond

What the Mounjaro label says

Mounjaro is a once-weekly injection approved for type 2 diabetes in adults and children 10 and older, and to reduce cardiovascular risk in adults with type 2 diabetes at high risk [1]. Its label has a dedicated section on acute gallbladder disease. In the adult placebo-controlled trials, acute gallbladder disease (cholelithiasis, biliary colic and cholecystectomy) was reported by 0.6% of patients on Mounjaro and 0% on placebo [1].

The statement in that section is diagnostic rather than pharmacological: if cholelithiasis is suspected, gallbladder diagnostic studies and clinical follow-up are indicated [1].

What links tirzepatide and the gallbladder

Tirzepatide activates both GIP and GLP-1 receptors and delays gastric emptying [1]. A 2024 review of GLP-1-based therapies says they potentially increase the risk of biliary disease [4]. Gallstone formation has been documented after surgically induced rapid weight loss, the setting in which ursodiol was tested [2].

Ursodiol: what the trial evidence shows

Ursodiol (ursodeoxycholic acid) has been tested as prophylaxis during rapid weight loss after bariatric surgery.

In a multicenter, randomized, double-blind, placebo-controlled trial, adults with a BMI of 40 or higher and a normal intraoperative gallbladder ultrasound received ursodiol 300, 600 or 1,200 mg daily, or placebo, starting within 10 days after gastric bypass and continuing for 6 months [2]. Of 233 patients with at least one postoperative ultrasound, gallstones appeared at 6 months in 32% of the placebo group, 13% of the 300 mg group, 2% of the 600 mg group and 6% of the 1,200 mg group; the 600 mg and 1,200 mg doses were significantly better than placebo (P<0.001) [2]. The authors concluded that 600 mg daily is effective prophylaxis after gastric-bypass-induced rapid weight loss [2].

That trial studied patients after gastric bypass, not people taking tirzepatide, so it does not show whether ursodiol prevents gallstones during Mounjaro treatment.

Pain medicines and antispasmodics

We found no study that tested NSAIDs, acetaminophen, antispasmodics such as hyoscine butylbromide or dicyclomine, or opioid analgesics specifically in people taking tirzepatide who have biliary pain.

What the label does address is absorption. Mounjaro delays gastric emptying and may change how oral medicines are absorbed; the label says to monitor oral drugs that depend on threshold concentrations for efficacy and those with a narrow therapeutic index, such as warfarin [1]. In an interaction study, peak acetaminophen concentration fell 55% and was delayed about 1 hour after a first 5 mg tirzepatide dose; at week 6 on 15 mg there was no meaningful effect on peak concentration or timing, and total exposure was unchanged [1].

How large the risk is in pooled data

A 2023 systematic review and meta-analysis of 9 randomized trials with 9,871 participants found the composite of gallbladder or biliary disease was significantly more common with tirzepatide than with placebo or basal insulin (RR 1.97, 95% CI 1.14 to 3.42); cholelithiasis and cholecystitis were not individually significantly increased [3].

Across the class, a 2025 meta-analysis of 21 trials and 99,599 patients found GLP-1 receptor agonists increased gallbladder disorders by 26% overall [5]. Results differ by population: a 2025 meta-analysis of 13 trials in 26,894 people with obesity but without diabetes reported that semaglutide raised gallbladder-related disorders while tirzepatide showed no significant biliary risk [6].

Pancreatitis is a separate warning

The same label has a separate warning for acute pancreatitis, with persistent or severe abdominal pain, sometimes radiating to the back. It says that if pancreatitis is suspected, Mounjaro should be discontinued and appropriate management started [1].